By co-delivering tumor antigens (like peptides from glypican-3, an HCC antigen) with a potent trainer like BCG or a synthetic β-glucan conjugate, one could stimulate both innate training and adaptive specific immunity [45,46]. Here, GPC3 is linked to hepatocellular carcinoma.